Targeting of mTORC2 may have advantages over selective targeting of mTORC1 in the treatment of malignant pheochromocytoma (Q41457277)

30 September 2017

title

Targeting of mTORC2 may have advantages over selective targeting of mTORC1 in the treatment of malignant pheochromocytoma (English)

1 reference

30 September 2017

1 reference

Xiaohua Zhang

1

1 reference

30 September 2017

Xianjin Wang

2

1 reference

30 September 2017

Tianyuan Xu

3

1 reference

30 September 2017

Shan Zhong

4

1 reference

30 September 2017

Zhoujun Shen

5

1 reference

30 September 2017

publication date

11 February 2015

1 reference

30 September 2017

1 reference

30 September 2017

volume

36

1 reference

30 September 2017

issue

7

1 reference

30 September 2017

page(s)

5273-5281

1 reference

Rationale for anti-angiogenic therapy in pheochromocytoma and paraganglioma.

30 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-3187-7

Molecular and therapeutic advances in the diagnosis and management of malignant pheochromocytomas and paragangliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-3187-7

Novel and evolving therapies in the treatment of malignant phaeochromocytoma: experience with the mTOR inhibitor everolimus (RAD001).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-3187-7

Current and future treatments for malignant pheochromocytoma and sympathetic paraganglioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-3187-7

Updated and new perspectives on diagnosis, prognosis, and therapy of malignant pheochromocytoma/paraganglioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-3187-7

An expanding role for mTOR in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-3187-7

Where is mTOR and what is it doing there?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-3187-7

mTOR kinase inhibitors as potential cancer therapeutic drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-3187-7

mTOR signaling at a glance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-3187-7

Targeting mTOR: prospects for mTOR complex 2 inhibitors in cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-3187-7

Active-site inhibitors of mTOR target rapamycin-resistant outputs of mTORC1 and mTORC2

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-3187-7

Beyond rapalog therapy: preclinical pharmacology and antitumor activity of WYE-125132, an ATP-competitive and specific inhibitor of mTORC1 and mTORC2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-3187-7

An ATP-competitive mammalian target of rapamycin inhibitor reveals rapamycin-resistant functions of mTORC1

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-3187-7

Effective and selective targeting of leukemia cells using a TORC1/2 kinase inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-3187-7

Targeting the mTOR kinase domain: the second generation of mTOR inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-3187-7

Targeting of mTORC2 prevents cell migration and promotes apoptosis in breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-3187-7

Autophagy is a survival mechanism of acute myelogenous leukemia precursors during dual mTORC2/mTORC1 targeting

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-3187-7

Impact of dual mTORC1/2 mTOR kinase inhibitor AZD8055 on acquired endocrine resistance in breast cancer in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-3187-7

Rapamycin inhibits mTORC1, but not completely.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-3187-7

Mechanisms of mTOR inhibitor resistance in cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-3187-7

PP242 suppresses cell proliferation, metastasis, and angiogenesis of gastric cancer through inhibition of the PI3K/AKT/mTOR pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-3187-7

mTOR: from growth signal integration to cancer, diabetes and ageing

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/25666752

12 December 2020

inferred from PubMed ID database lookup

Malignant pheochromocytoma and paraganglioma: future considerations for therapy

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/25666752

12 December 2020

inferred from PubMed ID database lookup

1 reference

https://pubmed.ncbi.nlm.nih.gov/25666752

12 December 2020

inferred from PubMed ID database lookup

Identifiers

DOI

10.1007/S13277-015-3187-7

1 reference

Dimensions Publication ID

30 September 2017

1001451104

0 references

Fatcat ID

release_zrp7mcfryvbfdiz3cljixkfsmy

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/zrp7mcfryvbfdiz3cljixkfsmy

24 November 2022

mapped directly with Wikidata item

1 reference